Stockholm Uppsala Europe s creative life science hub

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Stockholm Uppsala Europe s creative life science hub"

Transcription

1 Stockholm Uppsala Europe s creative life science hub Life Science Day 9th Swiss-Scandinavian Bio-Business Seminar Feb 5th Zürich

2 Stockholm Business Region Development AB The official investment promotion agency of Stockholm Mission: Attracting investments to the Stockholm-Uppsala region - Establishments - Industrial co-operations - VC

3 A great place to live! 3rd best city to live in globally by the Economist Intelligence Unit in Toronto 2. Montreal 3. Stockholm 4. Amsterdam 5. San Francisco 6. Melbourne 7. Zurich 8. Washington, DC 9. Sydney 10. Chicago Sourcw:

4 A safe place to live 4th safest city to live in globally by the Economist Intelligence Unit in Tokyo 2. Singapore 3. Osaka 4. Stockholm 5. Amsterdam 6. Sydney 7. Zurich 8. Toronto 9. Melbourne 10. New York City 50 cities were ranked on: Digital security Health Security Infrastructure Personal safety Source:

5 Recently Stockholm has received much attention as a successful Start up Scen. This is also the case in London and Berlin - But in Stockholm some of the companies have kicked of and become Billion dollar companies. "Stockholm is Europe's start-up superstar The New York Times (2013) "Stockholm is the home to some of the continent s most impressive tech start-ups of recent years Financial Times (2014) "Sweden offers an extremely competitive, largely corruption-free economy with access to new products, technologies, skills, and innovations U.S. Department of State (2013) "Stockholm is one of Europe's most vibrant, and underrated, digital scenes" The Guardian (2013)

6 Areas of excellence: Oncology Neuroscience Metabolic diseases Regenerative medicine Cardiovascular disease Infectious disease, Inflammation & Immunology Digital health

7 Strong and established ICT, life science & healthcare sectors Stockholm/Uppsala region with organizations that can drive digital health forward Renowned healthcare institutions Healthcare Leading ICT companies headquartered/r&d active ICT DH Life science Strong presence of globally leading pharma/med tech DH ecosystem participants

8

9

10 Companies Oncology: Affibody Biovica International ModPro AB NeoDynamics NoseLabs AB Oss-Design AB SCIBASE AB Spiber Technologies AB XSpray Digital health: Biosync Tech AB DD Innovation AB Hoa s Tool Shop AB Inerventions AB Mando Group AB MID AB One Lab Quick Posture Sw. AB SciLife Clinic AB Neuro: AlzeCure BioChromix AB Glucox Biotech AB Infectious Diseases, Inflammation & Immunology: Abera Bioscience Affibody Athera Biotech. AB Diamyd Medical AB(publ) Episurf Medical (publ) Glucox Biotech AB IsletOne Therapeutics ModPro AB Q-linea AB Scandinavian Biopharma Swecure AB Viscogel AB Metabolic Diseases: Diamyd Medical AB(publ) Glucox Biotech AB Mando Group AB Other: BioLamina AB Bio-Works Tech. AB CathPrint AB Corline Systems AB Dilafor AB Gradientech AB MID AB OssDsign AB Premune SensAbues AB Senzime AB Spiber Technologies AB Sportglass AB SymCel Sverige AB Xbrane Bioscience

11 Challenge Mental illness is the number one contributor to disease burden worldwide - more than cancer or cardiovascular disease. Er logga här Our solution Using our digital service - an easy to implement professional system, which consist of a mobile app for the client and a web app for the therapist - psychological treatment can be twice as efficient as it is today. This has been proven in a large RCT at Linköping University. Market Potential Costs for outpatient treatment of depression is $12.5 billion annually only in the U.S. Early development Company name: Category : Sub category: Location : Hoa s Tool Shop AB E-health Clinical psychology Stockholm Proof of concept CE-marking Commercialised

12 CHALLENGE Psychological disorders, such as depression, are major health problems, which lowers the quality of life for individuals and generates enormous costs for society. Mental illness cost more than $80 billion every year, only in the US. Even if psychological treatment has a success rate of 70 % for depression and anxiety treatment, only one third of patients get professional help by a therapist. More cost- and time effective treatment formats must be developed to meet the demands. BUSINESS MODEL Our service is easy to implement and therefore we can sell our service as a subscription model directly on the internet and skip complicated implementation processes. We will charge a monthly fee per active therapist using the service. Also, we will charge the end-users (patients) after the treatment is over, since the app can be used as a relapse prevention tool. Our tool has been sold in Sweden in a non-clinical context. We have had paying customers that have stayed with us for over two years. SOLUTION Our mission is to make psychotherapy so effective that everybody in need can get help. Using our digital service - an easy to implement professional system, which consist of a mobile app for the client and a web app for the therapist - psychological treatment can be twice as efficient as it is today. This means that waiting lists can be cut, healthcare companies can be more profitable and that patients can get healthier faster. Already proven in a large scientific study that showed that our service, together with four face-to-face sessions with a therapist is as effective as traditional CBT treatment including ten face-toface sessions. Our starting point is depression treatment, but the vision is that our digital service becomes a platform for all types of psychotherapy. MARKET Estimated cost of depression alone is $160 million per 1 million inhabitants in high-income countries. Costs for outpatient treatment of depression is $12.5 billion annually in the U.S. Moreover, during a one-year period, anxiety disorders will affect 14% of the population and depression will affect 6%. About 8.7 million people in the U.S. receive treatment for depression each year. In the U.S. there are approximately 600,000 mental health professionals. If we reach a 20 % market penetration and charge our service $100/professional/month, we will have an annual revenue of $144 M.

13 PROGRESS Development We have a working product that has been proven to work in a large clinical study. The study included 26 therapists at three clinics in Stockholm and Linköping. The study showed that our service, together with four face-to-face sessions is as effective as traditional CBT treatment including ten face-to-face sessions. The study will be published in a large psychiatric journal later this year. Next steps Our next step is to bring proof of concept to the tool on the open market. During Q1 and Q we will establish beta customers and try the tool on the market in Sweden. Also, we are looking to expand in the U.S. during Q2 with beta testing. Cigna, one of the largest insurance companies in the U.S. has shown great interest in our solution. OTHER INFORMATION Our product has been up and running since 2011 and sold to professionals in a non-clinical context and used for leadership coaching. However, with the latest clinical study that was finished May 2013, a clinical approach has been established. The company is tightly connected to Linköpings University and one of the most leading professors within the field of digitally distributed psychological treatment. Three studies have already been published on our tool and more studies are about to be published. Financials (SEK) Revenue EBIT Balance sheet total 605 T SEK -172 T SEK Five Valuation Largest Owners - Shares - (%) - Hoa Ly 39 John Airaksinen 32 Niklas Laninge 13 Albert Örwall 6 Jonas Jendi 6 Other 106 T SEK 532 T SEK 41 T SEK 283 T SEK Founded 2011 Employees (FTE) 4 How much funding in total has been raised in previous rounds?

14 TRACK RECORD AND EXPERTISE BOARD OF DIRECTORS AND MANAGEMENT After founding Hoa's Tool Shop in February 2011, the company was named one of Europe s most promising startups by Wired Magazine, listed as one of Sweden s top 25 web entrepreneurial companies by Internetworld and selected as one of nine young innovative Swedish companies to receive the Vinnova Vinn-Nu grant of In addition, Hoa's Tool Shop s app was shortlisted for a Swedish Golden Mobile Award. In 2013, the magazine Veckans Affärer, named Hoa s Tool Shop as as one of the most promising startups in Sweden. Our team has a unique combination of tech and design skills, business experience, research skills and deep knowledge of behavioral science. No pure tech team, nor any team with only psychologists would be able to provide a service like this. The company is headed by Hoa Ly (CEO), psychologist and researcher on digitally distributed therapy at Linköpings University. Hoa is doing research with the most prosperous scientists in the world within this field, including professor Gerhard Andersson and professor Pim Cuijpers. Hoa s research has been acknowledged in many parts of the world after a TEDx-talk and presentations at conferences. WHAT ARE WE LOOKING FOR? Hoa Ly John Airaksinen Niklas Laninge Albert Örwall Jonas Jendi CEO & co-founder Product manager & co-founder Community manager & co-founder Developer & co-founder Chairman & co-founder Hoa's Tool Shop is a privately held company with paying customers and small running costs. The company is interested in finding active financial investors with a view of taking the company to an international market. During Q3 2014, Hoa's Tool Shop is looking to expand the team with tech competence and sales staff to be able to go on to a commercializing phase. We are looking for an investment in the range of 500 k k, which would give us a runway of months with six employees. Contact information Hoa Ly, CEO +46 (0)

15 Criteria Impact / solve real problems Innovation Height Good management, trustworthy and suitable for the task Relatively mature, but may still be in development Strong intention to seek contact with investors, partners and to expand Academic engagement / interaction Have funds to match grant funding Being situated in the Stockholm / Uppsala region Looking for partners in industry Looking for investment of approx. SEK 5-50 million

16 Achivements Life Sciences, investments Approx 200 opportunities 13 visits of foreign journalists Anchored partners to continously receive high quality companies to Hotlist

17 Challenge Pathogens such as HIV, malaria and TB are too clever and complex for normal simple vaccines Vaccines need to be more sophisticated Our solution Abera has developed a universal platform that is more efficient, safe and has lower production time and cost compared to conventional vaccine technologies Vaccine candidates in pre-clinical phase: Streptococcus Pneumoniae and Tuberculosis Vaccine candidates in discovery phase: Chlamydia and Therapeutic Cancer B IO S C IEN C E Market Potential The WHO estimates that the vaccine market will be worth 100 BUSD by 2025 The vaccine market grows rapidly with a growth rate of 10-15% (compared to 5-7% for the global pharmaceutical market) Early development Company name: Category : Sub category: Location : Abera Bioscience Biotech Vaccine Development Stockholm Proof of concept Clinical phase Commercialised

18 Challenge Neurodegenerative diseases, e.g. Alzheimer s Disease (AD), are debilitating CNS conditions for which there is no curative or preventive treatment available. The field is hampered by limited disease understanding, difficulties to set appropriate diagnosis and inconclusive clinical trials. Our solution Identify and pursue drug targets that exhibit a clear linkage to well-defined patient populations. Combine technology and biology innovation to deliver efficacious therapies. Market Potential Approximately 115 million people are estimated to be suffering from AD in 2050, indicating a significant market potential for a novel disease modifying therapy. Early development Company name: Category : Sub category: Location : ALZECURE DRUG DEVELOPMENT NEURODEGENERATION STOCKHOLM Proof of concept CE-marking Commercialised

19 Challenge Need for better care of cardiovascular disease (CVD) patients Inflammation is not specifically addressed by current treatments Our solution PC-mAb to prevent complications in CVD CVDefine kit to identify patients that are most likely to benefit from treatment Market Potential CVD is the leading cause of death in the developed world Innovative Biopharmaceuticals for Cardiovascular Disease Treatment and Prevention Company name: Category : Sub category: Diagnostics Location : Athera Biotechnologies AB Drug development/biotech Therapeutic Antibodies/Companion Stockholm PC-mAb has first in class potential and targets the inflammatory component of CVD Discovery Preclinical development Clinical development Commercialized

20 Challenge How will the cancer disease develop? Will the patient respond to chemo-therapy? How do we know if a cancer treatment gives desired effect? Can we increase the development success rate of new cancer drugs? Our solution DiviTum has the ability to prognosticate cancer disease development DiviTum has the ability to predict patient response to therapy DiviTum can monitor the effect of a cancer treatment DiviTum can predict response and identify optimal patient cohorts, accelerating drug development Company name: Category : Sub category: Location : Biovica International Medtech Diagnostics Uppsala Market Potential 29 million people are living with cancer globally (5-year prevalence according to Globocan) Market potential estimated to >1,5 Billion $US globally Early development Proof of concept CE-marking Commercialized

21 Challenge What substances trigger our immune cells to move to the site of infection? What substances can counteract that cancer cells spread in the body? Our solution CellDirector can determine which substances that triggers immune cells or make cancer cells migrate CellDirector shortens the time for drug development Market Potential Cell based assays will be used earlier in the drug discovery process Microfluidic assays save time and costs with increased quality in results Early development Company name: Gradientech AB Proof of concept Category : BIOTECH CE-marking Sub category: CELL BASED ASSAYS Location : UPPSALA Commercialised

22 Challenge Spasticity causes pain and difficulties to move for people with e.g. CP and stroke Available treatments are expensive and associated with pain and heavy side effects Our solution A body suit system, Mollii, that reduces spasticity and increases patient activity and quality of life Cost-efficient and less side-effects compared to existing options for spasticity management Market Potential 3.5M patients in US and Western Europe On average EUR spent on spasticity management per patient per year in these countries Company name: Category : Sub category: Location : Inerventions AB Medtech Assistive Devices Stockholm Early development Proof of concept CE-marking Commercialised

23 SENZIME Senzime AB is a bio-tech company based in Uppsala, Sweden. The company develops and markets a unique and proprietary enzyme based biosensor technology with a wide applicability throughout different medical and bio/chemical processes and industries. Senzime focuses the following application areas: Biotechnology - Process control in the development and production of pharmaceuticals Health Care/Med Tech - Online monitoring Early development Company name: Category : Sub category: Location : Senzime AB Biotech/Med Tech Monitoring Devices/Hospital Equipment Uppsala Proof of concept Med Tech CE-marking Commercialised - Biotech

24 Challenge Rising prevalence of allergies No existing cure against allergy Our solution Our technology is directed towards stimulation of the immune system, which is required for proper activation of immunological tolerance and prevention of allergy Market Potential 11 million infants are born in the western world annually. 40 % of these infants develop allergy Early development Company name: Category: Sub category: Location: Swecure AB BIOTECH PHARMACEUTICALS, PROBIOTICS STOCKHOLM Proof of concept CE-marking Commercialised

25 Challenge There is a need for improved efficacy in modern vaccines Adjuvants play a significant role for improved vaccines, but few have the prerequisites to reach the market Our solution ViscoGel - proven safety and efficacy as vaccine adjuvant in Phase I/II clinical trial Regulatory uncomplicated proprietary technology with low COGS Market Potential Global vaccine market USD 28 bn (2010) New adjuvants are expected to be a major growth driver in the vaccine field. Early development Company name: Category : Sub category: Location : Viscogel AB Biotech Vaccine development and drug delivery Solna Proof of concept CE-marking Commercialised

26 Challenge Health professionals are still using analog methods for measuring movement. Lab testing is scarce & expensive Our solution Software using affordable off-the-shelf gaming sensor for 3D imaging Screening, analysis & user feedback Monitoring of progress over time Market Potential 1 in 3 people globally have movement disorders. Cost in USA = $565b/year 1 in 3 people over 65 fall each year. Cost in Sweden = 24.6b SEK/year 100m in EU have musculoskeletal chronic pain and 40% remain undiagnosed. Early development Company name: Category : Sub category: Location : Quick Posture Sweden AB DIGITAL HEALTH HEALTH SCREENING SOFTWARE STOCKHOLM Proof of concept CE-marking Commercialised

27 Thank you Thank you!

IMI2: why, what, how?

IMI2: why, what, how? IMI2: why, what, how? The Right prevention and treatment, to the right patient, at the right time Isabelle Thizon-de Gaulle VP, Strategic initiatives & Scientific relations Sanofi R&D Innovative Medicines

More information

Active Biotech Group Interim Report 1 January 30 September 1999

Active Biotech Group Interim Report 1 January 30 September 1999 Active Biotech Group Interim Report 1 January 30 September 1999 The new annual forecast shows a considerably better result. Sale of the property in Solna expected to be completed before the end of the

More information

An Exclusive Interview with Dr Jan-Anders Karlsson

An Exclusive Interview with Dr Jan-Anders Karlsson Dr Jan-Anders Karlsson took over the helm as the CEO of S*BIO from January 2005. He has extensive experience in the pharmaceutical industry, with many proven successes in the drug discovery area. Dr Karlsson

More information

The Cell Therapy Catapult

The Cell Therapy Catapult The Cell Therapy Catapult Keith Thompson CEO January 29 2013 info@ct.catapult.org.uk Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing

More information

Join our scientific talent community

Join our scientific talent community Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into

More information

The Commercialization of Technology Concepts into Medical Products

The Commercialization of Technology Concepts into Medical Products The Commercialization of Technology Concepts into Medical Products Kevin J. Scanlon, Ph.D. New Zealand 2006 International BioScience Overview Pharmaceutical Industry Biotechnology Startups Investment Community

More information

The Swedish Drug Development Pipeline. December 2013. & overview of Swedish companies with R&D activities in Sweden

The Swedish Drug Development Pipeline. December 2013. & overview of Swedish companies with R&D activities in Sweden The Swedish Drug Development Pipeline & overview of Swedish companies with R&D activities in Sweden December 2013 This report is compiled by SwedenBIO with support from VINNOVA and Business Sweden Table

More information

The Swedish Drug Development Pipeline. Dec. 2013. Sara Gunnerås, Senior Manager Science & IP, SwedenBIO SwedenBIO CEO Summit 2013, AstraZenaca Mölndal

The Swedish Drug Development Pipeline. Dec. 2013. Sara Gunnerås, Senior Manager Science & IP, SwedenBIO SwedenBIO CEO Summit 2013, AstraZenaca Mölndal The Swedish Drug Development Pipeline & overview of companies with R&D activities in Sweden Dec. 2013 Sara Gunnerås, Senior Manager Science & IP, SwedenBIO SwedenBIO CEO Summit 2013, AstraZenaca Mölndal

More information

New Millennium Indian Technology Leadership Initiative

New Millennium Indian Technology Leadership Initiative New Millennium Indian Technology Leadership Initiative A Unique Indian Public-Private Partnership Dr. D. Yogeswara Rao Head Technology Networking and Business Development Division Council of Scientific

More information

THE VIRAL HEPATITIS CONGRESS 2015. 10 12 September 2015, Kap Europa, Frankfurt, Germany THE VIRAL HEPATITIS CONGRESS. Scientific Programme

THE VIRAL HEPATITIS CONGRESS 2015. 10 12 September 2015, Kap Europa, Frankfurt, Germany THE VIRAL HEPATITIS CONGRESS. Scientific Programme THE VIRAL HEPATITIS CONGRESS THE VIRAL HEPATITIS CONGRESS 2015 10 12 September 2015, Kap Europa, Frankfurt, Germany Scientific Programme PRE-CONGRESS WORKSHOP SPONSOR ACHILLION Achillion is seeking to

More information

Alzheimer s Impact on the American People and the Economy

Alzheimer s Impact on the American People and the Economy www.alz.org Public Policy Office 202 393 7737 p 1212 New York Avenue, NW 866 865 0270 f Suite 800 Washington, DC 20005-6105 Testimony of Harry Johns, President and CEO of the Alzheimer s Association Fiscal

More information

The Swedish Drug Development Pipeline 2014

The Swedish Drug Development Pipeline 2014 The Swedish Drug Development Pipeline 2014 and an overview of swedish r&d companies 2013 december 2014 this report is compiled by swedenbio with support from vinnova 2 the swedish drug development pipeline

More information

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

More information

Diabetes & blindness. due to DME BLINDNESS IN EUROPE

Diabetes & blindness. due to DME BLINDNESS IN EUROPE Diabetes & blindness due to DME BLINDNESS IN EUROPE Blindness is a life-changing disability which puts a heavy strain on the daily lives of sufferers, their families, and society at large. Today, 284 million

More information

MULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA

MULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA MULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA Submission to the ACT Legislative Assembly Health, Ageing, Community and Social Services Inquiry into the exposure draft of the Drugs

More information

BUSINESS OPPORTUNITIES IN BIOTECHNOLOGY, PHARMACY AND LIFE SCIENCES

BUSINESS OPPORTUNITIES IN BIOTECHNOLOGY, PHARMACY AND LIFE SCIENCES BUSINESS OPPORTUNITIES IN BIOTECHNOLOGY, PHARMACY AND LIFE SCIENCES HEALTHCARE BIOTECHNOLOGY In Spain the development of ageing medicine presents an excellent business opportunity because the population

More information

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups Open Innovation@BayerHealthCare Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed to

More information

The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry

The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Talentmark Consulting Product Driven People Solutions Press Release The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Cambridge

More information

Getting Started: Conducting Clinical Trials in Ontario

Getting Started: Conducting Clinical Trials in Ontario Getting Started: Conducting Clinical Trials in Ontario Ontario offers compelling advantages as a location for conducting clinical trials. From world-class leadership in research to globally recognized

More information

Public funding policies: which options for small innovative companies in 2009. Biotech SMEs in the EU: how to improve access to finance

Public funding policies: which options for small innovative companies in 2009. Biotech SMEs in the EU: how to improve access to finance Public funding policies: which options for small innovative companies in 2009 Biotech SMEs in the EU: how to improve access to finance Dirk Carrez Director, EuropaBio EuroBio - 25 September 2009 (Lille)

More information

September 29, About BIO

September 29, About BIO The Comments of the Biotechnology Industry Organization on the Discussion Paper on Compulsory Licenses Published by the Department of Industrial Policy and Promotion within India's Ministry of Commerce

More information

IDSC White Paper Series:

IDSC White Paper Series: 310 N. Main St., Suite 301 Chelsea, MI 48118. USA 734-433-9670 I N T E R N A T I O N A L D I S C O V E R Y S E R V I C E S & C O N S U L T I N G IDSC White Paper Series: Commercial Valuations and Due Diligence

More information

The Future of Healthcare Services:

The Future of Healthcare Services: The Future of Healthcare Services: Is faster-than-market growth in your company s future? João Seabra, President Siemens Healthcare Western Europe and Western Africa * The healthcare market is changing

More information

ADMEDUS ANNOUNCES FURTHER DATA FROM HERPES SIMPLEX VACCINE TRIAL

ADMEDUS ANNOUNCES FURTHER DATA FROM HERPES SIMPLEX VACCINE TRIAL ADMEDUS Ltd ABN 35 088 221 078 REGISTERED OFFICE: Level 1, 197 Adelaide Terrace Perth Western Australia 6000 PO Box 6879 East Perth Western Australia 6892 ASX ANNOUNCEMENT T +61 (0)8 9266 0100 F +61 (0)8

More information

Neural Diagnostics Pty Ltd

Neural Diagnostics Pty Ltd Neural Diagnostics Pty Ltd EVestG (ElectroVestibulography) In the absence of competing technology, research to date indicates NDPL s EVestG platform technology can objectively and in real time: o Separate

More information

Improving Pharmaceutical Innovation By Building A More Comprehensive Database On Drug Development and Use

Improving Pharmaceutical Innovation By Building A More Comprehensive Database On Drug Development and Use Advancing Healthcare Improving Pharmaceutical Innovation By Building A More Comprehensive Database On Drug Development and Use Jonathan S Leff March 13, 2015 Available Metrics Point to Long-Term Decline

More information

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010 U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade December 2010 Table of Contents Notes on Methodology 8 Market Introduction and Segmentation Introduction

More information

Increasing Innovation in R&D - Seizing early stage external growth opportunities

Increasing Innovation in R&D - Seizing early stage external growth opportunities Increasing Innovation in R&D - Seizing early stage external growth opportunities Paul R. Eynott, PhD sanofi-aventis, US paul.eynott@sanofi-aventis.com -1- Sommaire -2- CHRISTOPHER A. VIEHBACHER Chief Executive

More information

Automating Cell Biology Annual general meeting, September 7, 2015. Phase Holographic Imaging www.phiab.se

Automating Cell Biology Annual general meeting, September 7, 2015. Phase Holographic Imaging www.phiab.se Automating Cell Biology Annual general meeting, September 7, 2015 www.phiab.se 1 PHASE HOLOGRAPHIC IMAGING (PHI) Began as a research project at Lund University, Sweden, in 2000 Founded in 2004 Sales in

More information

SWECARE FOUNDATION. Uniting the Swedish health care sector for increased international competitiveness

SWECARE FOUNDATION. Uniting the Swedish health care sector for increased international competitiveness SWECARE FOUNDATION Uniting the Swedish health care sector for increased international competitiveness SWEDEN IN BRIEF Population: approx. 9 800 000 (2015) GDP/capita: approx. EUR 43 300 (2015) Unemployment

More information

From IMI to IMI2. Hugh Laverty PROTECT London

From IMI to IMI2. Hugh Laverty PROTECT London From IMI to IMI2 Hugh Laverty 20.02.2015 PROTECT London Innovative Medicines Initiative: Joining forces in the healthcare sector The biggest public/private partnership in Life Science aiming to: Make drug

More information

Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis

Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis May 25, 2015 Contact: Shikha Virdi 905-919-0200 ext. 5504 Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis Rebif now reimbursed under Ontario Drug Benefit Program

More information

Stem Cell & Regenerative Medicine Research: A Canadian Science & An Innovation Winner

Stem Cell & Regenerative Medicine Research: A Canadian Science & An Innovation Winner Stem Cell & Regenerative Medicine Research: A Canadian Science & An Innovation Winner Author: Dr. Michael Rudnicki, OC, FRSC Scientific Director & CEO, Stem Cell Network Director, Sprott Centre for Stem

More information

TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...

TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending... CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and

More information

Objectives: Perform thorough assessment, and design and implement care plans on 12 or more seriously mentally ill addicted persons.

Objectives: Perform thorough assessment, and design and implement care plans on 12 or more seriously mentally ill addicted persons. Addiction Psychiatry Program Site Specific Goals and Objectives Addiction Psychiatry (ADTU) Goal: By the end of the rotation fellow will acquire the knowledge, skills and attitudes required to recognize

More information

PROMETIC LIFE SCIENCES INC.

PROMETIC LIFE SCIENCES INC. PROMETIC LIFE SCIENCES INC. Investor Update July to September 2002 This present release must be considered as the quarterly report to shareholders. 1. Letter to Shareholders Dated November 21, 2002 2.

More information

EXECUTIVE SUMMARY Prepared for: Pharmaceutical Research and Manufacturers of America (PhRMA) Prepared by: Battelle Technology Partnership Practice

EXECUTIVE SUMMARY Prepared for: Pharmaceutical Research and Manufacturers of America (PhRMA) Prepared by: Battelle Technology Partnership Practice EXECUTIVE SUMMARY Prepared for: Pharmaceutical Research and Manufacturers of America (PhRMA) Prepared by: Battelle Technology Partnership Practice Battelle is the world s largest non profit independent

More information

Il ruolo dell Advisory Group for «Health, Wellbeing and Demographic Change» in Horizon 2020

Il ruolo dell Advisory Group for «Health, Wellbeing and Demographic Change» in Horizon 2020 Il ruolo dell Advisory Group for «Health, Wellbeing and Demographic Change» in Horizon 2020 Lucia Monaco Horizon 2020 Advisory Group, Societal Challenges 1: Health, Demographic Change and Wellbeing Seminario:

More information

Australia Life Sciences Market

Australia Life Sciences Market Australia Life Sciences Market Monique Roos, Commercial Specialist U.S. Commercial Service, Sydney, Australia November 2014 Geographical Size Population Density More than 80% of population in this ring

More information

New strategies in the field of rare diseases: a comprehensive international approach Runolfur Palsson

New strategies in the field of rare diseases: a comprehensive international approach Runolfur Palsson 17 January 2012 Annual Conference of the Icelandic Medical Association New strategies in the field of rare diseases: a comprehensive international approach Runolfur Palsson Rare diseases In Europe, a disease

More information

TOP 10 TRENDS IN HEALTHCARE, MEDICAL. HJ ABDUL AZIZ ABDUL RAHMAN Chief Executive Officer

TOP 10 TRENDS IN HEALTHCARE, MEDICAL. HJ ABDUL AZIZ ABDUL RAHMAN Chief Executive Officer TOP 10 TRENDS IN HEALTHCARE, MEDICAL AND PHARMACEUTICAL INDUSTRY HJ ABDUL AZIZ ABDUL RAHMAN Chief Executive Officer KPJSeremban Specialist Hospital KPJ SEREMBAN SPECIALIST HOSPITAL Presented by : Hj Abd

More information

A Star Track for the best connected health startups in the Nordics

A Star Track for the best connected health startups in the Nordics A Star Track for the best connected health startups in the Nordics Nordic Connected Health Star Track accelerates business development and international scaling of Nordic startups. The Nordic countries

More information

Investing in Incubation A View from Stevenage Bioscience Catalyst (SBC)

Investing in Incubation A View from Stevenage Bioscience Catalyst (SBC) Investing in Incubation A View from Stevenage Bioscience Catalyst (SBC) Miranda Knaggs, Business Manager You re smart. We care. Join a community making a difference... Building a world class Open Innovation

More information

Public-Private Partnerships for Bridging the Innovation Gap in Personalized Medicine

Public-Private Partnerships for Bridging the Innovation Gap in Personalized Medicine Public-Private Partnerships for Bridging the Innovation Gap in Personalized Medicine Martin LeBlanc, President and CEO, Caprion The 2014 ISPIM Americas Innovation Forum October 6, 2014 1 CHALLENGES FOR

More information

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Tariq Sadat PhD Candidate School of Economics, Finance and Marketing, RMIT University, Australia Roslyn

More information

Life Science Sector Opportunities Northern Ireland. Clinical Trials. investni.com

Life Science Sector Opportunities Northern Ireland. Clinical Trials. investni.com Life Science Sector Opportunities Northern Ireland investni.com Introduction Clinical trials commonly refer to testing the effectiveness of experimental drugs and are typically categorised into four phases;

More information

ITT Advanced Medical Technologies (Ileri Tip Teknolojileri)

ITT Advanced Medical Technologies (Ileri Tip Teknolojileri) ITT Advanced Medical Technologies (Ileri Tip Teknolojileri) ITT Advanced Medical Technologies (Ileri Tip Teknolojileri) is a biotechnology company (SME) established in Turkey. Its activity area is research,

More information

Federal Funding for Technological Revolutions: Biotechnology and Healthcare Highlights

Federal Funding for Technological Revolutions: Biotechnology and Healthcare Highlights ADVANCED TE CHNOLOGY P ROGRAM The Advanced Technology Program Federal Funding for Technological Revolutions: Biotechnology and Healthcare Highlights April 2006 National Institute of Standards and Technology

More information

The Broad Benefits of AIDS Research

The Broad Benefits of AIDS Research The Broad Benefits of AIDS Research Many new treatments for diseases such as cancer, hepatitis and heart disease have arisen from research on HIV/AIDS. Since the beginning of the epidemic, AIDS research

More information

A targeted approach to infectious diseases and microbiology

A targeted approach to infectious diseases and microbiology What is a Technological Research Institute? A Technological Research Institute is an interdisciplinary institute bringing together industry and public research skills through medium-to long-term strategic

More information

Active Biotech Group Half Year Report January June 1999

Active Biotech Group Half Year Report January June 1999 Active Biotech Group Half Year Report January June 1999 SmithKline Beecham gives top priority to the ETEC-vaccine - completes Phase III trials in a new project organisation Investing in increased production

More information

Time to stop wasting time Getting novel medicines to patients. 4 th World Health Summit, Berlin Severin Schwan, 22 October 2012

Time to stop wasting time Getting novel medicines to patients. 4 th World Health Summit, Berlin Severin Schwan, 22 October 2012 Time to stop wasting time Getting novel medicines to patients 4 th World Health Summit, Berlin Severin Schwan, 22 October 2012 Pharma Business Model for Innovation Challenges Summary Pharma Industry Unlimited

More information

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K. GEOVAX LABS, INC. (Exact name of registrant as specified in its charter)

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K. GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):

More information

An integrated global healthcare company

An integrated global healthcare company An integrated global healthcare company 1 A Mission to create healthier communities globally Zydus Cadila is dedicated to life In all its dimensions. Our world is shaped by a passion for innovation, commitment

More information

TERM SHEET EXAMPLE. 1 P age

TERM SHEET EXAMPLE. 1 P age 1 P age TERM SHEET EXAMPLE BIOTECHCO Overview & Business Strategy BIOTECHCO (the licensor), located in North Dakota, has a proprietary technology called ZIP that can generate fully human antibodies with

More information

Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany

Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany Agenda Section 1 Overview on the Top Ten Pharmaceutical Companies Section

More information

PharmD Postdoctoral Fellowship Program

PharmD Postdoctoral Fellowship Program Novartis Institutes for Biomedical Research and Massachusetts College of Pharmacy and Health Sciences, Worcester/Manchester PharmD Postdoctoral Fellowship Program Introduction Fellowship training in the

More information

DanDrit Biotech OTCQB:DDRT

DanDrit Biotech OTCQB:DDRT DanDrit Biotech OTCQB:DDRT Developing the World s First Colorectal Cancer Vaccine Investor Dagen - Copenhagen. March 2015 Disclaimer This presentation may contain forward-looking statements, including

More information

+ REACTIONS. Kantar Health discusses. disease (IBD) market. pharma.

+ REACTIONS. Kantar Health discusses. disease (IBD) market. pharma. REACTIONS the evolving inflammatory bowel disease (IBD) market Kantar Health discusses the increased prevalence of ibd, how it will affect the current and future market, and opportunities for pharma. april

More information

Company Presentation

Company Presentation Company Presentation DISCLAIMER This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of amp biosimilars

More information

Identification of a problem, e.g., an outbreak Surveilance Intervention Effect

Identification of a problem, e.g., an outbreak Surveilance Intervention Effect EPIDEMIOLOGY EPIDEMIOLOGY Epidemiology is a cornerstone of the control of infectious diseases. Statens Serum Institut s epidemiological activities cover a wide field, from surveillance of diseases and

More information

Egészség a jövő Európájában [Health for Europe s future]: Health 2020

Egészség a jövő Európájában [Health for Europe s future]: Health 2020 Egészség a jövő Európájában [Health for Europe s future]: Health 2020 Why Health 2020? In the WHO European Region, health is improving overall but not as rapidly as it could or should. Countries have different

More information

Committee on Finance to create sustainable longterm economic growth in Canada

Committee on Finance to create sustainable longterm economic growth in Canada Biotechnology Innovation: A submission to the House of Commons Standing Committee on Finance to create sustainable longterm economic growth in Canada EXECUTIVE SUMMARY: The bio-economy in Canada represents

More information

Institute for OneWorld Health

Institute for OneWorld Health Institute for OneWorld Health a nonprofit pharmaceutical company Oxymoron no more: nonprofits can deliver medicines for the poor of the world January 10, 2005 Victoria Hale, PhD CEO, OneWorld Health The

More information

Molecular Biotechnology Master s Degree Program

Molecular Biotechnology Master s Degree Program > APPLIED LIFE SCIENCES Master s Degree Program: > FULL TIME Molecular Biotechnology Master s Degree Program www.fh-campuswien.ac.at My Occupational Future. Your Career Opportunities Biotechnology is one

More information

The ASGCT invites you to submit your research to the largest scientific conference of its kind!

The ASGCT invites you to submit your research to the largest scientific conference of its kind! American Society of Gene & Cell Therapy A N N U A L M E E T I N G th May 16-19 2 0 1 2 Philadelphia PA USA The ASGCT invites you to submit your research to the largest scientific conference of its kind!

More information

Merck Strategy. Richard T. Clark Chief Executive Officer and President

Merck Strategy. Richard T. Clark Chief Executive Officer and President Merck Strategy Richard T. Clark Chief Executive Officer and President The Global Health Care Market is Challenging but Creates Great Opportunity for Merck Challenges Declining success rates in new drug

More information

Unlock Your Global Business Potential: Supporting Life Sciences in the UK

Unlock Your Global Business Potential: Supporting Life Sciences in the UK Unlock Your Global Business Potential: Supporting Life Sciences in the UK Dr Mark Treherne, Chief Executive, Life Science Investment Organisation Health Research Authority 31 st March, 2014 THE UK HAS

More information

Business development and strategic planning services. for life sciences and medtech ventures

Business development and strategic planning services. for life sciences and medtech ventures Business development and strategic planning services for life sciences and medtech ventures ttopstart - Business development and strategic planning services Design: Studio Edwin de Boer Business development

More information

Since achieving independence from Great Britain in 1963, Kenya has worked to improve its healthcare system.

Since achieving independence from Great Britain in 1963, Kenya has worked to improve its healthcare system. Medical Management Plan Kenya OVERVIEW Company Mission Our mission is to encourage young people to volunteer for worthwhile work in developing countries. We expect that doing this kind of voluntary work

More information

Research and Development in the Czech Republic. Mr. Jiri Krechl Head of R&D Support Department

Research and Development in the Czech Republic. Mr. Jiri Krechl Head of R&D Support Department Research and Development in the Czech Republic Mr. Jiri Krechl Head of R&D Support Department CZECHINVEST Investment and Business Development Agency Ministry of Industry and Trade CzechInvest Investment

More information

Orphan Pharma: pathfinders for an increasingly specialised industry

Orphan Pharma: pathfinders for an increasingly specialised industry Orphan Pharma: pathfinders for an increasingly specialised industry Foreword We are continuing our series by profiling the R&D and Clinical Development leadership of European and North American specialty

More information

Roche Position on Human Stem Cells

Roche Position on Human Stem Cells Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with

More information

Grow your business via Västerbotten. Regional Partner

Grow your business via Västerbotten. Regional Partner Grow your business via Västerbotten Anti-infective research in Umeå Unique insight on the pathogenicity of microbes and novel approaches on antibiotics 3 universities with 35.000 students (Umeå University

More information

Strategic Vision. Jörn Aldag Chief Executive Officer

Strategic Vision. Jörn Aldag Chief Executive Officer AGENDA 01 1. Strategic Vision 2. uniqure s Modular Platform & Cross Referencing 3. Gene Therapy for Liver Disease and Metabolic Disorder 4. Breakthroughs in Lysosomal Storage Disease Break 5. Gene Therapy

More information

Health Innovation. Innovation for health includes the. diagnostics and medical devices, as

Health Innovation. Innovation for health includes the. diagnostics and medical devices, as BIO-INNOVATION Health Innovation Innovation for health includes the development of new drugs, vaccines, diagnostics and medical devices, as well as new techniques in process engineering and manufacturing,

More information

UNCOVERING OPPORTUNITIES IN THE BIOTECH SECTOR - BRAZIL

UNCOVERING OPPORTUNITIES IN THE BIOTECH SECTOR - BRAZIL UNCOVERING OPPORTUNITIES IN THE BIOTECH SECTOR - BRAZIL INTRODUCTION BY INNOVATION CENTRE DENMARK IN SAO PAULO BRAZILIAN BIOTECHNOLOGY SECTOR The Ministry of Science, Technology and Innovation (MCTI) considers

More information

Janssen Research & Development 3210 Merryfield Row San Diego, CA 92121

Janssen Research & Development 3210 Merryfield Row San Diego, CA 92121 NHLBI SAN DIEGO INNOVATION CONFERENCE JUNE 11, 2013 Janssen Research & Development 3210 Merryfield Row San Diego, CA 92121 Agenda Speaker Bios 10:30-11:00 a.m. Registration 11:00-11:15 a.m. Welcome Remarks

More information

Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA

Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA Media Release Basel, 28 June 2016 Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA OCREVUS is the first investigational medicine

More information

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies Greetings from Chicago! Beaches Yes! Pharma Beginnings! Bogota 1974 Selling Drugs in Colombia Global

More information

Whitepaper: MSL and Sales Strategies for the US Oncology Market

Whitepaper: MSL and Sales Strategies for the US Oncology Market Whitepaper: MSL and Sales Strategies for the US Oncology Market Oncology: where an expansive market opportunity interests with an extremely high cost of failure. Companies have been built, sold, and failed

More information

FINDING PROTEINS THAT HIT THE MARK PROVEN TRACK-RECORD OF PROTEOMICS EXPERTISE

FINDING PROTEINS THAT HIT THE MARK PROVEN TRACK-RECORD OF PROTEOMICS EXPERTISE FINDING PROTEINS THAT HIT THE MARK PROVEN TRACK-RECORD OF PROTEOMICS EXPERTISE Bioanalytical Services Fit-for-Purpose Assays Biomarker Discovery and Development Proven track-record of proteomics expertise

More information

CLINICAL RESEARCH NETWORK

CLINICAL RESEARCH NETWORK CLINICAL RESEARCH NETWORK Introduction The vision of the National Institute for Health Research (NIHR) is to improve the health and wealth of the nation through research. This document sets out how the

More information

Clinical medicine in 1987

Clinical medicine in 1987 Clinical medicine in 1987 Rheumatoid arthritis Crohn s disease Triumph of translational medicine Cytokine-targeting antibodies Leukocyte adhesion blockers Kinase inhibitors (cancer, chronic inflammatory

More information

J.P. Morgan 2016 Healthcare Conference CEO. January 12, 2016 NYSE: Q. Copyright 2016 Quintiles

J.P. Morgan 2016 Healthcare Conference CEO. January 12, 2016 NYSE: Q. Copyright 2016 Quintiles J.P. Morgan 2016 Healthcare Conference Tom Pike CEO January 12, 2016 Copyright 2016 Quintiles NYSE: Q Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking

More information

Biotechnology Current Trends

Biotechnology Current Trends Biotechnology Current Trends Biotechnology Key Trends - Higher growth will be continued on Biotechnology sector during the next four years, around 14% annually. - Asia pacific countries are the most promising

More information

Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies

Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies PRESS RELEASE Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies Servier Also Enters Into Exclusive Global

More information

Thinking about TB elimination at home and abroad

Thinking about TB elimination at home and abroad Global tuberculosis incidence Thinking about TB elimination at home and abroad Neil W. Schluger, M.D. Professor of Medicine, Epidemiology, and Environmental Health Science Columbia University Overall:

More information

Interim report, 1 January 31 March Cash flow from operating activities was TSEK -1,272 (-3,255)

Interim report, 1 January 31 March Cash flow from operating activities was TSEK -1,272 (-3,255) AroCell AB (publ) Interim report, 1 January 31 March 2016 Net sales were TSEK 0 (0) Loss after financial items was TSEK -2,842 (-2,402) Earnings per share where SEK -0.10 (-0.10) Cash flow from operating

More information

Tuberculosis OUR MISSION THE OPPORTUNITY

Tuberculosis OUR MISSION THE OPPORTUNITY Tuberculosis OUR MISSION Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. Our Global Health Program is

More information

European Biotech & Pharma Dr. Patrik Frei May 2014 Tokyo

European Biotech & Pharma Dr. Patrik Frei May 2014 Tokyo European Biotech & Pharma Dr. Patrik Frei May 2014 Tokyo 1 Overview 1. Venture Valuation 2. Trends in the EU Biotech & Pharma 3. Overview European Biotechs / Clusters 2 Valuation Valuation Mission Independent

More information

2014 Report: biotechnologies in the Italian pharmaceutical sector

2014 Report: biotechnologies in the Italian pharmaceutical sector 2014 Report: biotechnologies in the Italian pharmaceutical sector In collaboration with Assobiotec Executive summary Executive summary Executive summary Biotechnologies have always influenced all spheres

More information

OPKO Health to Acquire Bio-Reference Laboratories

OPKO Health to Acquire Bio-Reference Laboratories OPKO Health to Acquire Bio-Reference Laboratories - Complementary in-depth expertise in diagnostics business with state of the art experience in use of genomic data for personalized therapy - Acquisition

More information

New York Bio Conference 2016. Mark J. Alles Chief Executive Officer

New York Bio Conference 2016. Mark J. Alles Chief Executive Officer New York Bio Conference 2016 Mark J. Alles Chief Executive Officer Great Progress AGE 72 World Life Expectancy 2005-2014* 17 new drugs for rare diseases 71.5 71 Two new MS drugs First drug to target root

More information

Rare disease research in FP7, Outlook in Horizon 2020, IRDiRC

Rare disease research in FP7, Outlook in Horizon 2020, IRDiRC Rare disease research in FP7, Outlook in Horizon 2020, IRDiRC Dr. Iiro Eerola Scientific Project Officer Unit for Personalised Medicine Directorate F Health DG Research and European Commission iiro.eerola@ec.europa.eu

More information

Hepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL

Hepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Hepatitis C Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Recent Advances in Hepatitis C Appreciation that many patients are undiagnosed Improved screening to identify infected persons Assessment

More information

Facts and Figures. The World Health Report 2003 Shaping the Future. Life expectancy

Facts and Figures. The World Health Report 2003 Shaping the Future. Life expectancy World Health Organization Facts and Figures The World Health Report 2003 Shaping the Future Life expectancy Life expectancy at birth in 2002 reached a global average of 65.2 years, compared with 46.5 years

More information

OraSure Technologies, Inc. Jefferies 2015 Global Healthcare Conference

OraSure Technologies, Inc. Jefferies 2015 Global Healthcare Conference OraSure Technologies, Inc. Jefferies 2015 Global Healthcare Conference Forward-Looking Statements These slides and the associated presentation contain certain forward-looking statements, including statements

More information

THE BIOTECH & PHARMACEUTICAL INDUSTRY

THE BIOTECH & PHARMACEUTICAL INDUSTRY THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues

More information

Industry Insight - Indian Biopharma

Industry Insight - Indian Biopharma Brochure More information from http://www.researchandmarkets.com/reports/2043221/ Industry Insight - Indian Biopharma Description: Biopharmaceuticals are complex macromolecules (Large molecules) created

More information